IP Library › Granted Patent US 10,258,692
Granted Patent B2
US 10,258,692 · App. 14/407,858 · Granted Apr 16, 2019

Oral pharmaceutical formulation of BCS class III molecules

Inventors: Caroline Ailhas (Alizay, FR); Catherine Herry (Saint-Ouen du Tilleul, FR)
Assignee: ETHYPHARM
A61K47/14A61K9/0095A61K9/1075A61K9/1617A61K9/2013A61K9/48A61K31/197A61K47/10A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,258,692
App. No.
14/407,858
Granted
Apr 16, 2019
Kind
B2
Abstract

The present invention concerns an oral pharmaceutical formulation made from a microemulsion between an aqueous solution comprising at least one BCS (Biopharmaceutics Classification System) class III active principle and one oily phase comprising an oily vehicle that is self-emulsifiable on contact with water.

Claims (8)

1. An oral pharmaceutical formulation in tablet form consisting of:

a neutral carrier impregnated with an oil-in-water microemulsion, dried and compressed with compression excipients,

said oil-in-water microemulsion being between an aqueous solution comprising water and baclofen and an oil phase comprising an oil excipient self-emulsifiable in contact with water, said oil excipient self-emulsifiable in contact with water being a mixture of mono-, bi- and triglycerides of PEG-8 esterified fatty acids in the proportion of 50 to 80% caprylic acid and 20 to 50% capric acid, said oil-in-water microemulsion comprising from 2 to 30% oil phase and from 70% to 98% aqueous solution, based on the total weight of the oil-in-water microemulsion;

wherein said tablet form contains residual moisture of less than 5%.

2. The formulation according to claim 1 , said oil excipient self-emulsifiable in contact with water having an HLB value higher than 12.

3. The formulation according to claim 1 , wherein said oil phase represents 5 to 25% of the oil-in-water microemulsion.

4. The formulation according to claim 1 , said oil excipient self-emulsifiable in contact with water being contained in a ratio of 1:10 to 1:100 by weight relative to baclofen.

5. A method of treatment of alcohol dependence or for the maintaining of alcohol abstinence, comprising administration of the formulation according to claim 1 to a patient in need.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2016
From: AILHAS, CAROLINE; HERRY, CATHERINE
To: ETHYPHARM
Reel/Frame 037409/0116 →
Priority Claims (1)
FR 12 55593 · Jun 14, 2012 · national
Continuity (1)
Related Publication 20150165032A1 · Jun 18, 2015